CAMBRIDGE, Mass. and MUNICH, June 30, 2011 /PRNewswire/ —
Metamark Genetics, a privately-held oncology molecular diagnostic
company, and Definiens, the leading Health Image
Intelligence™ company, today announced a development and
commercialization partnership in which Metamark will combine its
proprietary multiplex protein detection platform with image
analysis technology developed jointly with Definiens to deliver
innovative prognostic and predictive assays for early-stage
cancers.
“Definiens is a clear world leader in quantitative digital
pathology and in the analysis of biomarkers in tissue image data,”
said Eric Devroe, Ph.D., Vice President of Business & Strategy
Development for Metamark. “We see great synergy in combining
Definiens’ technology and expertise with Metamark’s unique
understanding of tumor heterogeneity and insight into the molecular
drivers regulating tumor formation and aggression. We believe that
this partnership will enable us to co-develop and implement unique
and important image analysis tools.”
Metamark’s quantitative diagnostic approach can identify and
account for small regions of molecularly aggressive cancer cells
within an otherwise indolent tumor. The company is developing a
portfolio of prognostic and predictive assays with the ability to
address the “heterogeneous” nature of tumors not only between one
patient and the next, but also within an individual patient’s
tumor.
Definiens has made ground-breaking achievements in the field of
biomarker development based on its highly robust and scalable image
analysis framework that enables scientists and clinicians to
rapidly extract comprehensive biomarker and morphology expression
profiles and to identify a relevant subset of descriptors by
correlating them against patient outcomes.
“Definiens is pleased to partner with Metamark Genetics, and to
incorporate our image and data analysis software technology into
Metamark’s pioneering Oncology diag
‘/>”/>
